Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 6/2018

01-06-2018 | Headache (RB Halker, Section Editor)

An Up to Date Review of Pseudotumor Cerebri Syndrome

Authors: John Glenn Burkett, Jessica Ailani

Published in: Current Neurology and Neuroscience Reports | Issue 6/2018

Login to get access

Abstract

Purpose of Review

Idiopathic intracranial hypertension (IIH), pseudotumor cerebri syndrome (PTCS), and benign intracranial hypertension are all terms that have been used for a neurologic syndrome consisting of elevated intracranial pressure (ICP), headache and vision loss without mass lesion or underlying infection or malignancy. In this review article, categorization, diagnostic criteria, symptom management strategies, and disease treatment options for pseudotumor cerebri syndrome will be discussed.

Recent Findings

The Idiopathic Intracranial Hypertension Treatment Trial has now proven that acetazolamide should be the first line therapy in primary PTCS, but other treatment options exist in patients who cannot tolerate acetazolamide or in selected cases, which requires surgical intervention for PTCS which acutely threatens vision. Headache has also been shown to require focused treatment beyond therapies that lower ICP, specifically targeting coexistent primary headache disorders and medication overuse.

Summary

Advances in treatment and diagnostic modalities have improved understanding of PTCS types and their treatment. The pathophysiology of primary PTCS, however, remains incompletely understood, but continued evaluation of cerebrospinal fluid flow dynamics, aquaporins, hormones, natriuretic peptides, and the link with female gender and obesity may lead to future answers.
Literature
1.
Degnan A, Levy L. Pseudotumor cerebri: brief review of clinical syndrome and imaging findings. Am J Neuroradiol. 2011;32(11):1986–93.CrossRefPubMed
2.
Johnston I. The historical development of the pseudotumor concept. Neurosurg Focus. 2001;11(2):1–9.CrossRef
3.
Friedman D, Liu G, Digre K. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013;81:1159–65.CrossRefPubMed
4.
5.
6.
Riggeal B, Bruce B, Saindane A, Ridha M, Kelly L, Newman N, et al. Clinical course of idiopathic intracranial hypertension with transverse sinus stenosis. Neurology. 2012;80:289–95.CrossRefPubMed
7.
Rohr A, Dörner L, Stingele R, Buhl R, Alfke K, Jansen O. Reversibility of venous sinus obstruction in idiopathic intracranial hypertension. AJNR Am J Neuroradiol. 2007;4:656–9.
8.
• Mollan S, Ali F, Hassan-Smith G, Botfield H, Friedman D, Sinclair A. Evolving evidence in adult idiopathic intracranial hypertension: pathophysiology and management. J Neurol Neurosurg Psychiatry. 2016;87:982–92. Recent review of PTCS pathophysiology and treatment trials. CrossRefPubMedPubMedCentral
9.
Warner J, Larson A, Bhosale P, Digre K, Henley C, Alder S, et al. Retinol-binding protein and retinol analysis in cerebrospinal fluid and serum of patients with and without idiopathic intracranial hypertension. J Neuroophthalmol. 2007;27:258–62.CrossRefPubMed
10.
Tabassi A, Salmasi A, Jalali M. Serum and CSF vitamin A concentrations in idiopathic intracranial hypertension. Neurology. 2005;64:1893–6.CrossRefPubMed
11.
• Libien J, Kupersmith M, Blaner W, McDermott M, Gao S, Liu Y, et al. Role of vitamin A metabolism in IIH: results from the idiopathic intracranial hypertension treatment trial. J Neurol Sci. 2017;372:78–84. Vitamin A metabolite levels in patients of the Idiopathic Intracranial Hypertension Treatment Trial. CrossRefPubMed
12.
• Subramaniam S, Fletcher W. Obesity and weight loss in idiopathic intracranial hypertension. J Neuroophthalmol. 2017;37:197–205. Recent review of published literature regarding the association of PTCS and obesity. CrossRefPubMed
13.
Portelli M, Papageorgiou P. An update on idiopathic intracranial hypertension. Acta Neurochir. 2016;159(3):491–9.CrossRefPubMed
14.
Kilgore K, Lee M, Leavitt J, Mokri B, Hodge D, Frank R, et al. Re-evaluating the incidence of idiopathic intracranial hypertension in an era of increasing obesity. Ophthalmology. 2017;124:697–700.CrossRefPubMedPubMedCentral
15.
Sinclair A, Ball A, Burdon M, Clarke C, Stewart P, Curnow S, et al. Exploring the pathogenesis of IIH: an inflammatory perspective. J Neuroimmunol. 2008;201-202:212–20.CrossRefPubMed
16.
• Sinclair AJ, Markey KA, Uldall M, Cato L, Miah M, Botfield H, et al. Idiopathic intracranial hypertension, hormones, and 11beta-hydroxysteroid dehydrogenases. J Pain Res 2016;9:223–232. Review of PTCS’ correlation with hormones and obesity.
17.
Markey K, Ottridge R, Mitchell J, Rick C, Woolley R, Ives N, et al. Assessing the efficacy and safety of an 11β-Hydroxysteroid dehydrogenase type 1 inhibitor (AZD4017) in the idiopathic intracranial hypertension drug trial, IIH:DT: clinical methods and Design for a Phase II randomized controlled trial. JMIR Res Protoc. 2017;6:e181.CrossRefPubMedPubMedCentral
18.
Skau M, Goetze J, Rehfeld J, Jensen R. Natriuretic pro-peptides in idiopathic intracranial hypertension. Regul Pept. 2010;164:71–7.CrossRefPubMed
19.
Ameli P, Madan M, Chigurupati S, Yu A, Chan S, Pattisapu J Effect of acetazolamide on aquaporin-1 and fluid flow in cultured choroid plexus. Acta Neurochir Suppl 2012;113:59–64.
20.
Radhakrishnan K, Thacker A, Bohlaga N, Maloo J, Gerryo S. Epidemiology of idiopathic intracranial hypertension: a prospective and case-control study. J Neurol Sci. 1993;116(1):18–28. (epidemiology)CrossRefPubMed
21.
Raoof N, Sharrack B, Pepper I, Hickman S. The incidence and prevalence of idiopathic intracranial hypertension in Sheffield, UK. Eur J Neurol. 2011;18:1266–8.CrossRefPubMed
22.
Kesler A, Stolovic N, Bluednikov Y, Shohat T. The incidence of idiopathic intracranial hypertension in Israel from 2005 to 2007: results of a nationwide survey. Eur J Neurol. 2014;21:1055–9.CrossRefPubMed
23.
•• Matthews Y, Dean F, Lim M, Mclachlan K, Rigby A, Solanki G, et al. Pseudotumor cerebri syndrome in childhood: incidence, clinical profile and risk factors in a national prospective population-based cohort study. Arch Dis Child. 2017;102:715–21. National prospective cohort study looking at 185 cases in the Britsh Paediatric Surveillance Unit. CrossRefPubMed
24.
•• Sundholm A, Burkill S, Sveinsson O, Piehl F, Bahmanyar S, Nilsson Remahl A. Population-based incidence and clinical characteristics of idiopathic intracranial hypertension. Acta Neurol Scand. 2017;136:427–33. (Obesity). Evaluation of the incidence of PTCS in Sweden using national patient registry. CrossRefPubMed
25.
•• Wall M, Kupersmith M, Kieburtz K, Corbett J, Feldon S, Friedman D, et al. The idiopathic intracranial hypertension treatment trial. JAMA Neurolgy. 2014;71:693. Outlines the baseline clinical characteristics of patients enrolled in the IIHTT–701.CrossRef
26.
Wall M. The headache profile of idiopathic intracranial hypertension. Cephalalgia. 1990;10:331–5.CrossRefPubMed
27.
•• Friedman D, Quiros P, Subramanian P, Mejico L, Gao S, McDermott M, et al. Headache in idiopathic intracranial hypertension: findings from the idiopathic intracranial hypertension treatment trial. Headache J Head Face Pain. 2017;57:1195–205. Findings from IIHTT regarding headache and PTCS. CrossRef
28.
Thambisetty M, Lavin P, Newman N, Biousse V. Fulminant idiopathic intracranial hypertension. Neurology. 2007;68:229–32.CrossRefPubMed
29.
Stevens S, Rizk H, Golnik K, Andaluz N, Samy R, Meyer T, et al. Idiopathic intracranial hypertension: contemporary review and implications for the otolaryngologist. Laryngoscope. 2017;128:248–56.CrossRefPubMed
30.
Smith JL. Whence pseudotumor cerebri? J Clin Neuroopthalmol. 1985;5:55–6.
31.
Friedman D, Jacobson D. Diagnostic criteria for idiopathic intracranial hypertension. Neurology. 2002;59:1492–5.CrossRefPubMed
32.
Kupersmith M, Gamell L, Turbin R, Peck V, Spiegel P, Wall M. Effects of weight loss on the course of idiopathic intracranial hypertension in women. Neurology. 1998;50:1094–8.CrossRefPubMed
33.
Johnson L, Krohel G, Madsen R, March G. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology. 1998;105:2313–7.CrossRefPubMed
34.
Handley J, Baruah B, Williams D, Horner M, Barry J, Stephens J. Bariatric surgery as a treatment for idiopathic intracranial hypertension: a systematic review. Surg Obes Relat Dis. 2015;11:1396–403.CrossRefPubMed
35.
• Ottridge R, Mollan S, Botfield H, et al. Randomised controlled trial of bariatric surgery versus a community weight loss programme for the sustained treatment of idiopathic intracranial hypertension: the idiopathic intracranial hypertension weight trial (IIH:WT) protocol. BMJ Open. 2017;7:e017426. Ongoing trial comparing bariatric surgery vs. weight loss program for treatment of primary PTCS. CrossRefPubMedPubMedCentral
36.
•• Smith S, Friedman D. The idiopathic intracranial hypertension treatment trial: a review of the outcomes. Headache J Head Face Pain. 2017;57:1303–10. Review summarizing the results of the IIHTT since 2014. CrossRef
37.
Thurtell M, Wall M. Idiopathic intracranial hypertension (pseudotumor cerebri): recognition, treatment, and ongoing management. Curr Treat Options Neurol. 2012;15:1–12.CrossRef
38.
Huna-Baron R, Kupersmith M. Idiopathic intracranial hypertension in pregnancy. J Neurol. 2002;249:1078–81.CrossRefPubMed
39.
40.
Fonseca P, Rigamonti D, Miller N, Subramanian P. Visual outcomes of surgical intervention for pseudotumour cerebri: optic nerve sheath fenestration versus cerebrospinal fluid diversion. Br J Ophthalmol. 2014;98:1360–3.CrossRefPubMed
41.
deSouza R, Toma A, Watkins L. Medication overuse headache—an under-diagnosed problem in shunted idiopathic intracranial hypertension patients. Br J Neurosurg. 2014;29:30–4.CrossRef
42.
Puffer R, Mustafa W, Lanzino G. Venous sinus stenting for idiopathic intracranial hypertension: a review of the literature. J NeuroInterv Surg. 2013;5:483–6.CrossRefPubMed
43.
Satti S, Leishangthem L, Chaudry M. Meta-analysis of CSF diversion procedures and dural venous sinus stenting in the setting of medically refractory idiopathic intracranial hypertension. Am J Neuroradiol. 2015;36:1899–904.CrossRefPubMed
44.
Metadata
Title
An Up to Date Review of Pseudotumor Cerebri Syndrome
Authors
John Glenn Burkett
Jessica Ailani
Publication date
01-06-2018
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 6/2018
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-018-0839-1

Other articles of this Issue 6/2018

Current Neurology and Neuroscience Reports 6/2018 Go to the issue

Epilepsy (CW Bazil, Section Editor)

Neurostimulation for Memory Enhancement in Epilepsy

Stroke (H Diener, Section Editor)

Circulating Troponin I Level in Patients with Acute Ischemic Stroke

Critical Care (SA Mayer, Section Editor)

Minimally Invasive Surgery for Intracerebral Hemorrhage

Neuroimaging (N Pavese, Section Editor)

Present and Future of Ultra-High Field MRI in Neurodegenerative Disorders

Movement Disorders (S Fox, Section Editor)

Disturbances of Sleep and Alertness in Parkinson’s Disease

Headache (RB Halker, Section Editor)

Exercise Headache: a Review